Acadian Asset Management
CPRX

Acadian Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Acadian Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-8,315
Closed -$205K – 2029
2026
Q1 		$205K Sell
8,315
-21,984
-73% -$524K ﹤0.01% 1575
2025
Q4 		$706K Buy
+30,299
New +$675K ﹤0.01% 1214
2025
Q3 		– Sell
-7,128
Closed -$154K – 1859
2025
Q2 		$154K Buy
7,128
+1,877
+36% +$44.3K ﹤0.01% 1347
2025
Q1 		$127K Sell
5,251
-15,296
-74% -$344K ﹤0.01% 1316
2024
Q4 		$428K Buy
+20,547
New +$441K ﹤0.01% 1107
2023
Q1 		– Sell
-30,153
Closed -$560K – 1772
2022
Q4 		$560K Sell
30,153
-860,904
-97% -$13.3M ﹤0.01% 1002
2022
Q3 		$11.4M Sell
891,057
-500,509
-36% -$5.93M 0.06% 244
2022
Q2 		$9.76M Sell
1,391,566
-130,143
-9% -$955K 0.05% 270
2022
Q1 		$12.6M Buy
1,521,709
+145,743
+11% +$1.03M 0.05% 276
2021
Q4 		$9.31M Sell
1,375,966
-58,984
-4% -$388K 0.03% 321
2021
Q3 		$7.6M Buy
1,434,950
+349,859
+32% +$1.91M 0.03% 360
2021
Q2 		$6.24M Sell
1,085,091
-119,587
-10% -$617K 0.02% 413
2021
Q1 		$5.55M Buy
1,204,678
+470,649
+64% +$1.87M 0.02% 447
2020
Q4 		$2.45M Buy
734,029
+35,702
+5% +$120K 0.01% 705
2020
Q3 		$2.07M Sell
698,327
-2,234
-0.3% -$8.74K 0.01% 658
2020
Q2 		$3.24M Sell
700,561
-163,586
-19% -$735K 0.01% 592
2020
Q1 		$3.33M Buy
864,147
+244,416
+39% +$1M 0.02% 471
2019
Q4 		$2.32M Buy
619,731
+400,629
+183% +$1.87M 0.01% 641
2019
Q3 		$1.16M Buy
219,102
+142,686
+187% +$760K 0.01% 849
2019
Q2 		$293K Buy
+76,416
New +$330K ﹤0.01% 1135
2018
Q4 		– Sell
-23,544
Closed -$89K – 1732
2018
Q3 		$89K Sell
23,544
-129,094
-85% -$404K ﹤0.01% 1233
2018
Q2 		$476K Buy
+152,638
New +$463K ﹤0.01% 902
2015
Q4 		– Sell
-4,185
Closed -$13K – 1420
2015
Q3 		$13K Buy
4,185
+3,635
+661% +$15.7K ﹤0.01% 1089
2015
Q2 		$2K Buy
+550
New +$2.19K ﹤0.01% 1313

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Acadian Asset Management's CPRX Position: Q2 2026 in Review

Acadian Asset Management sold out of Catalyst Pharmaceutical (CPRX) in Q2 2026, closing a stake of 8,315 shares — an estimated $205K sold.

Acadian Asset Management first reported a position in CPRX in Q2 2015 and held it in 24 quarters. The position peaked at $12.6M in Q1 2022. 395 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Acadian Asset Management reported no remaining Catalyst Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Acadian Asset Management sold 8,315 Catalyst Pharmaceutical shares in Q2 2026, an estimated $205K.
  • Acadian Asset Management first reported a position in Catalyst Pharmaceutical in Q2 2015 and held it in 24 quarters.
  • Acadian Asset Management's Catalyst Pharmaceutical position peaked at $12.6M in Q1 2022.
  • 395 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.